The authors wish to make the following corrections to this paper [1]:
Table 4.
Summary of microarrays for cmiRNA.
| Assay | Required Input (ng) | Probe Content |
|---|---|---|
| Affymetrix GeneChip miRNA Arrays 4.0 | 130 | miRBase v.20 |
| Agilent oligonucleotides microarrays | 100 | miRBase v.21 |
| Exiqon miRCURY LNA microRNA arrays | 30 | miRBase v.19 |
| µParaflo®Microfluidic Biochip Technology | 1000 | miRBase v.21 |
| 3D-Gene® | 2000 | miRBase v.21 |
should be replaced with
Table 4.
Summary of microarrays for cmiRNA.
| Assay | Required Input (ng) | Probe Content |
|---|---|---|
| Affymetrix GeneChip miRNA Arrays 4.0 | 130 | miRBase v.20 |
| Agilent oligonucleotides microarrays | 100 | miRBase v.21 |
| Exiqon miRCURY LNA microRNA arrays | 30 | miRBase v.19 |
| µParaflo®Microfluidic Biochip Technology | 1000 | miRBase v.21 |
| 3D-Gene® | 250 | miRBase v.21 |
The authors apologize for any inconvenience caused to the readers by these changes.
Reference
- 1.Ono S., Lam S., Nagahara M., Hoon D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015;4:1890–1907. doi: 10.3390/jcm4101890. [DOI] [PMC free article] [PubMed] [Google Scholar]